Winrevair, when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with PAH, trial data show.

Stem cell-derived conditioned medium, the liquid that remains after cells are cultured, reduced PAH signs in rats and cells, ...

Gossamer Bio has begun the process of acquiring Respira Therapeutics and its lead on-demand PH treatment candidate, RT234.

Columnist Jolie Lizana attended the Pulmonary Hypertension Association's (PHA) PHPN Symposium, which discussed PH research.